IPN : €99.80 €0.80 (0.81%)
Ipsen – Innovation for patient care
Ipsen receives CHMP negative opinion for palovarotene as a treatment for fibrodysplasia ossificans progressiva in E.U.
Ipsen presents Phase III NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience.
Among the top pharmaceutical companies in the world specializing in oncology, we address challenges posed by the most difficult-to-treat cancers.
With over 25 years of research, development and commercial experience in neuroscience, we are fully committed to improving health outcomes for patients suffering from debilitating neurological disorders.
We are committed to developing innovative solutions for people living with rare diseases. By focusing our efforts on these rare conditions, we make substantial impact in areas with significant unmet needs.
As a global biopharmaceutical company with a focus on innovation and specialty care, we have the ambition to build a robust, valuable, and sustainable portfolio of medicines to meet patients and their healthcare teams' needs.
2021 Integrated Annual Report
In 2021, we achieved incredible growth and change as we implemented our strategy; 'Focus. Together. For Patients & Society.' From growing our pipeline with external innovation to researching and developing new treatments, we're proud of our progress and excited to go further in 2022.
Discover our 2021 Annual Report
Careers at Ipsen
At Ipsen, we recognize that our employees are the cornerstone of our success. We offer exciting opportunities that will challenge your abilities, grow your career and reward your contribution while making a meaningful difference for patients and society.
Search Ipsen positions
We believe that great partnerships create great possibilities. We are on a mission to deliver at least one new molecular entity or meaningful indication each year and collaborations with other like-minded innovators are key for the next phase of our growth.
Visit our dedicated investor section to find more information on financial results, our financial calendar and more.
Ipsen anti-corruption system certification renewed in 2022